Open Label, Single Arm, Phase II Study Using R-COMP in Elderly Patients With Aggressive NHL.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00244127|
Recruitment Status : Unknown
Verified October 2005 by Zeneus Pharma.
Recruitment status was: Active, not recruiting
First Posted : October 25, 2005
Last Update Posted : October 28, 2005
|Condition or disease||Intervention/treatment||Phase|
|Aggressive Non-Hodgkin's Lymphoma in the Elderly.||Drug: Cyclophosphamide, oncovin, myocet, prednisone & rituximab (R-COMP)||Phase 2|
To evaluate the duration of remission, disease free survival and 2-year survival of R-COMP in first line therapy of elderly patients with advanced aggressive NHL.
To evaluate the tolerability of R-COMP in first line therapy of elderly patients with advanced aggressive NHL.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||75 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Cyclophosphamide, Oncovin, Myocet, Prednisone and Rituximab (R-COMP) in the Treatment of Elderly Patients With Aggressive NHL.|
|Study Start Date :||October 2002|
- Response rate
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00244127
|Universita Degli Studi Di Modena AZ Ospedaliere Policlinico|
|Modena, Italy, 41100|
|Leicester, United Kingdom|
|Principal Investigator:||Massimo Federico||Universita Degli Studi di Modena|